Track topics on Twitter Track topics that are important to you
Real-World Evidence Research to Explore Socioeconomic, Racial and Ethnic Disparities in Diabetes Treatment
KENILWORTH, N.J. – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that 25 studies, including new analyses for JANUVIA® (sitagliptin),STEGLATRO™(ertugliflozin) and studies of real-world data, are scheduled to be presented at the 79th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, June 7 - 11, 2019. Presentations include new analyses of data with JANUVIA from the Comparative Trials with Sitagliptin (CompoSIT) program.
Original Article: Merck to Present New Analyses for JANUVIA® (sitagliptin) and STEGLATRO™ (ertugliflozin), and Real-World Data Studies at the 79th Scientific Sessions of the American Diabetes AssociationNEXT ARTICLE
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...
Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...